{"id":80029,"date":"2018-06-26T08:22:23","date_gmt":"2018-06-26T15:22:23","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/06\/has-the-telomerase-revolution-arrived-part-one"},"modified":"2018-06-30T13:02:45","modified_gmt":"2018-06-30T20:02:45","slug":"has-the-telomerase-revolution-arrived-part-one","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/06\/has-the-telomerase-revolution-arrived-part-one","title":{"rendered":"Has the Telomerase Revolution Arrived? Part One"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/has-the-telomerase-revolution-arrived-part-one2.jpg\"><\/a><\/p>\n<p>Today, we have part one of a two-part interview with Dr. Michael Fossel, the driving force behind <a href=\"http:\/\/www.telocyte.com\/\">Telocyte<\/a>, a new company focused on telomerase therapy for various diseases, and a strong advocate of telomerase therapy to treat human disease over the past three decades.<\/p>\n<p>I interviewed Dr. Fossel as an individual thought leader in this field and not in his role representing Telocyte, so the opinions stated here are purely his own.<\/p>\n<p>Born in 1950, Michael Fossel grew up in New York and lived in London, Palo Alto, San Francisco, Portland, and Denver. He graduated cum laude from Phillips Exeter Academy, received a joint B.A. and M.A. in psychology in four years from Wesleyan University in Connecticut, and, after completing a Ph.D. in neurobiology at Stanford University in 1978, went on to finish his M.D. at Stanford Medical School in two and a half years. He was awarded a National Science Foundation Fellowship and taught at Stanford University, where he began studying aging with an emphasis on premature aging syndromes. Dr. Fossel was a Clinical Professor of Medicine at Michigan State University for almost three decades and taught the Biology of Aging at Grand Valley State University.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.leafscience.org\/has-the-telomerase-revolution-arrived\/\">https:\/\/www.leafscience.org\/has-the-telomerase-revolution-arrived\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Today, we have part one of a two-part interview with Dr. Michael Fossel, the driving force behind Telocyte, a new company focused on telomerase therapy for various diseases, and a strong advocate of telomerase therapy to treat human disease over the past three decades. I interviewed Dr. Fossel as an individual thought leader in this [\u2026]<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,32,269],"tags":[],"class_list":["post-80029","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-education","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/80029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=80029"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/80029\/revisions"}],"predecessor-version":[{"id":80248,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/80029\/revisions\/80248"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=80029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=80029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=80029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}